National Rosacea Society

LAURA GELLER BEAUTY FOUNDATION CELEBRATES 20 YEARS WITH NEW ACCOLADES AND CAMPAIGN

Retrieved on: 
Mercredi, janvier 31, 2024
Ageing, Heart, National Psoriasis Foundation, Let's Face It, QVC, Skin, Woman, NRS, Rosacea, Antioxidant, Beauty, National Rosacea Society, Face, Baking, Cosmetics

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Laura Geller Beauty, a pioneer in the makeup industry and known for artisan-crafted baked makeup, specifically formulated for mature skin, is celebrating its 20th-anniversary of its best-selling and cult-favorite product, Baked Balance-n-Brighten Color Correcting Foundation.

Key Points: 
  • NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Laura Geller Beauty, a pioneer in the makeup industry and known for artisan-crafted baked makeup, specifically formulated for mature skin, is celebrating its 20th-anniversary of its best-selling and cult-favorite product, Baked Balance-n-Brighten Color Correcting Foundation.
  • To mark this significant milestone, Laura Geller Beauty has launched the 'Let's Face It' campaign with a series of content to be leveraged across brand social channels and digital platforms.
  • "'Let's Face It' is an acknowledgment that we must change our beauty routines as we age," says Geller.
  • Laura Geller Beauty's products, including the best-selling Baked Balance-n-Brighten Color Correcting Foundation, are available on QVC, LauraGeller.com, Amazon, and other select retailers.

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Retrieved on: 
Vendredi, janvier 5, 2024
Marketing, National Rosacea Society, Entrepreneurship, Food, CEA, Minocycline, Rosacea, FDA, Capsule, NDA, Red, New Drug Application, Face, Patient, Food and Drug Administration, Erythema, Pharmaceutical industry

SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) --  Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company has submitted a New Drug Application (“NDA”) to the FDA seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd.
    “This NDA submission is a significant milestone for Journey Medical and we look forward to collaborating with the FDA during its review to bring DFD-29, a potentially differentiated, best-in-class oral rosacea treatment, one step closer to patients.
  • The NDA submission is supported by positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.
  • The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.
  • DFD-29 has the potential to become the only oral, systemic therapy to address both inflammatory lesions and erythema (redness) from rosacea, as demonstrated in the clinical trials.

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Retrieved on: 
Mardi, août 30, 2022
PPR, COVID-19, NDA, Safety, Securities Exchange Act of 1934, IGA, Securities Act of 1933, Research, NASDAQ, Doxycycline, Entrepreneurship, Independent Women Part I, Data, National Rosacea Society, Telangiectasia, Drug Quality and Security Act, S.A, Minocycline, SEC, Skin, U.S. Securities and Exchange Commission, Patent, Journal, Disorder, GLOBE, Fortress Biotech, Adult, Regulation, Marketing, Dermatology, Laboratory, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry, Dietary supplement, Rosacea

The Phase 3 clinical trials are part of a collaboration with Dr. Reddys Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program.

Key Points: 
  • The Phase 3 clinical trials are part of a collaboration with Dr. Reddys Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program.
  • In a Phase 2 multicenter clinical trial, DFD-29 achieved nearly double the efficacy compared to doxycycline capsules 40 mg on reducing total inflammatory lesions and Investigators Global Assessment (IGA) treatment success.
  • The MVOR-01 and MVOR-02 clinical trials are randomized in a 3:3:2 ratio to DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg), Oracea (Doxycycline capsules 40 mg) or placebo once daily for 16 weeks.
  • The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea (Doxycycline capsules 40 mg).

Global Dermatological Drug Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mai 20, 2022
Health, Pharmaceutical, Drinking, American Academy of Dermatology, American Academy, Population, Sol–gel process, Ageing, Medicine, Radiation, Acne, National Rosacea Society, Infection, US Foods, Skin, Incidence, Geography, COVID-19, Hair, Research, FDA, Projection, Psoriasis, Awareness, Smoking, Nail, Immunity, Technology, Dermatitis, Trauma, Wound healing, Adoption, CAGR, American Association, Growth, Prevalence, Tissue (biology), Petroleum jelly, Agriculture, Dietary supplement, Pharmaceutical industry, Dermatology

The "Global Dermatological Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dermatological Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dermatological Drug Market is projected to grow at a CAGR of 11.22% during the forecast period to reach US$47.892 billion by 2027, up from US$22.747 billion in 2020.
  • The global dermatological drug market is segmented by indication, route of administration, end-user, and geography.
  • Due to the simple availability of dermatological drugs, North America is estimated to account for a large proportion of the dermatological drug market over the forecast period.

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

Retrieved on: 
Jeudi, mars 17, 2022
Private Securities Litigation Reform Act, Journal, Rosacea, Minocycline, Plasma, Fortress Biotech, NASDAQ, Doxycycline, Patent, Marketing, Forward-looking statement, Adult, Roger O. Egeberg, Research, S.A, SEC, Ageing, Journal of the American Academy of Dermatology, PPR, Entrepreneurship, Prevalence, National Rosacea Society, Disorder, Safety, Incidence, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Telangiectasia, Skin, Securities Act of 1933, COVID-19, Regulation, GLOBE, Drug Quality and Security Act, Systematic review, Meta-analysis, Patient, Pharmaceutical industry, Dietary supplement, Dermatology

One trial is enrolling patients in the United States and the other is enrolling in the United States and Europe.

Key Points: 
  • One trial is enrolling patients in the United States and the other is enrolling in the United States and Europe.
  • The studies will be randomized in a 3:3:2 ratio to DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg), Oracea (Doxycycline capsules 40 mg) or placebo once daily for 16 weeks.
  • The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea (Doxycycline capsules 40 mg).
  • Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, stated, Reaching this milestone marks another important inflection point for Journey Medical.

HMP Global's Dermatology Week Announces Scholarship Program for Its Inaugural Educational Event

Retrieved on: 
Mercredi, juillet 28, 2021
Psoriasis, Dermatology, Organ systems, Medical specialties, National Psoriasis Foundation, National Rosacea Society

MALVERN, Pa., July 28, 2021 /PRNewswire-PRWeb/ -- HMP Global, the leading healthcare event and education company, today announced its Education Accelerator Initiative, an expansive scholarship program for the inaugural Dermatology Week event.

Key Points: 
  • MALVERN, Pa., July 28, 2021 /PRNewswire-PRWeb/ -- HMP Global, the leading healthcare event and education company, today announced its Education Accelerator Initiative, an expansive scholarship program for the inaugural Dermatology Week event.
  • Each day's programming is designed to address the needs of specialized dermatologists as well as those treating general patient populations.
  • The program has been developed in conjunction with and endorsed by the Dermatology Nurses' Association (DNA), the National Psoriasis Foundation (NPF) and the National Rosacea Society (NRS).
  • "Dermatology Week will be delivered by outstanding experts from across the nation who are actively shaping the future of dermatological care," said Dr. Gelfand.

Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

Retrieved on: 
Mercredi, juin 30, 2021
Organ systems, Dermatology, Acneiform eruptions, Integumentary system, National Rosacea Society, Rosacea

Claude Maraoui, President and Chief Executive Officer of Journey Medical, stated, DFD-29 has the potential to be an effective treatment option for those patients who suffer from rosacea.

Key Points: 
  • Claude Maraoui, President and Chief Executive Officer of Journey Medical, stated, DFD-29 has the potential to be an effective treatment option for those patients who suffer from rosacea.
  • We look forward to working with Dr. Reddys to further develop DFD-29 for the treatment of rosacea, which has already seen promising results in Phase 2 clinical trials.
  • The National Rosacea Society estimates 16 million U.S. based patients suffer from rosacea, demonstrating the sizeable market for this opportunity.
  • Journey Medical Corporation (Journey Medical) is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.

Global Rosacea Epidemiology and Patient Flow Report 2020-2035: Focus on US, Germany, France, Italy, Spain, UK, Japan, and G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Mercredi, mai 5, 2021
Health, General Health, Acneiform eruptions, Rosacea, Epidemiology, National Rosacea Society

b'The "Global Rosacea Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Rosacea Epidemiology and Patient Flow Analysis - 2021, provides Rosacea epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Rosacea Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Rosacea Epidemiology and Patient Flow Analysis - 2021, provides Rosacea epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Rosacea patients, history of the disease at the population level (Rosacea prevalence, Rosacea incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Rosacea patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Rosacea market sizing, assessing market potential, and developing drug forecast models\nIdentify Rosacea patients segments through age groups, gender, and disease sub-types\n'

HMP Global Announces Launch of Virtual Conference, Dermatology Week

Retrieved on: 
Mardi, janvier 26, 2021
Psoriasis, Organ systems, Medical specialties, National Rosacea Society, National Psoriasis Foundation, Dermatology

MALVERN, Pa., Jan. 26, 2021 /PRNewswire-PRWeb/ --As part of its continued mission to connect the global healthcare community with clinically relevant information and education that improves patient care, the world's largest healthcare event and education company, HMP Global, today announced the launch of Dermatology Week.

Key Points: 
  • MALVERN, Pa., Jan. 26, 2021 /PRNewswire-PRWeb/ --As part of its continued mission to connect the global healthcare community with clinically relevant information and education that improves patient care, the world's largest healthcare event and education company, HMP Global, today announced the launch of Dermatology Week.
  • Serving as official partners for Dermatology Week will be the National Psoriasis Foundation (NPF) and the National Rosacea Society (NRS).
  • Leading the development of the Dermatology Week program is a premier group of clinical experts lending a broad range of medical and clinical perspectives.
  • "Dermatology Week is a unique, distraction-free learning experience where the focus will be on dermatology, not destination," said Dr. Gelfand.

European Rosacea Market Analysis 2020: Treatment Options, Late Stage Clinical Trials Pipeline and Market Forecasts to 2024

Retrieved on: 
Mardi, octobre 6, 2020
Organ systems, Dermatology, Acneiform eruptions, RTT, Rosacea, Integumentary system, Market share, National Rosacea Society

DUBLIN, Oct. 6, 2020 /PRNewswire/ -- The "Europe Rosacea Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 6, 2020 /PRNewswire/ -- The "Europe Rosacea Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Rosacea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Rosacea market size and drug sales.
  • This research covers the following: Rosacea treatment options, Rosacea late stage clinical trials pipeline, Rosacea prevalence by countries, Rosacea market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.